Eiger BioPharmaceuticals to focus Avexitide for hyperinsulinemic hypoglycaemia indications
Eiger BioPharmaceuticals has revealed it will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycaemia...
top of page
Browse by category
Search
ARMMS-T2D: Surgery shows long-term success over standard diabetes management
Metabolic and bariatric surgery results in superior glycaemic control, less medication usage and high rates of remission of type 2...
NICE needs more evidence before recommending tirzepatide for T2DM treatment
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended tirzepatide (Mounjaro, developed by Eli Lilly) in...
Journal Watch 28/06/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Bariatric surgery reduces mortality in patients with obesity and sleep apnoea
Bariatric surgery was associated with a 42% lower risk of major adverse cardiovascular events (MACE), including heart failure, heart...
Despite lowering BMI threshold for eligibility, access to surgery remains low
Despite patient eligibility for bariatric surgery expanding over the last decade and its safety and effectiveness even further...
Metabolic surgery results in fewer heart attacks, strokes and death among patients with diabetes
Patients with diabetes and a history of metabolic surgery had significantly fewer heart attacks, strokes, hospitalisations and death,...
T2DM remains in remission six years after RYGB regardless of weight loss
More than half of patients (51%) with type 2 diabetes and a history of metabolic surgery experienced remission of their diabetes even if...
Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks
Phase 2 data for orforglipron (12 mg, 24 mg, 36 mg or 45 mg), a nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, has...
GLP-1-RA: Pfizer to continue danuglipron but discontinue lotiglipron
Pfizer will continue to progress its first full agonist oral glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate - danuglipron...
Browse by tag
bottom of page